Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission

NCT03333369 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Healthy
Schizotypal Personality

Interventions

DRUG: 200 mg levodopa/50 mg benserazide
DRUG: Dextrose

Sponsor

University of Zurich

Collaborators

[object Object]